Kymera Therapeutics (KYMR) Common Equity (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Common Equity data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 95.82% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 95.82% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 89.04% from the prior year.
• Common Equity for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
• Over the last five years, Common Equity for KYMR reached as high as $1.6 billion in Q4 2025 and fell as low as $395.0 million in Q4 2023.
• Historically, Common Equity has averaged $733.3 million across 5 years, with a median of $684.9 million in 2024.
• Across the five-year window, Common Equity dropped 22.88% in 2023 and soared 125.75% in 2024, its largest moves.
• Year by year, Common Equity stood at $490.2 million in 2022, then retreated by 19.42% to $395.0 million in 2023, then surged by 111.56% to $835.6 million in 2024, then jumped by 89.04% to $1.6 billion in 2025, then dropped by 2.53% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $946.3 million in Q3 2025.